MyPhenome
Commercial- Indications
- Obesity
Company intelligence / Profile preview
Phenomix Sciences has developed and commercialized MyPhenome™, the first precision medicine test for obesity phenotyping. The test uses genomics, metabolomics, and hormone analysis with AI algorithms to classify patients into one of four biological subtypes ("phenotypes") of obesity. Clinical research shows that using this information to guide therapy selection can double weight loss compared to standard approaches. The technology has been validated in prospective studies with major academic partners including Mayo Clinic. Over 80 clinics are using the product nationwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Phenomix Sciences.